Tianeptine for Treatment-Resistant Depression
Sponsor: |
The Hope for Depression Research Foundation |
Enrolling: |
Male and Female Patients |
Study Length: |
8 Weeks |
IRB Number: |
7944 |
U.S. Govt. ID: |
NCT04249596 |
Contact: |
Esteban Ceballos: 646-774-8677 / esteban.ceballos@nyspi.columbia.edu |
The purpose of this 8-week study is to evaluate the effectiveness of a medication called tianeptine for treating depression in people whose symptoms have not responded to two prior treatments. Tianeptine is an investigational drug. This means that it has not been approved for use by the United States Food and Drug Administration (FDA), the branch of the federal government that approves new drugs, but it has been approved by the European Regulatory Agency and has been used to treat depression in Europe, Asia, and South America since the 1980s.
This study is closed
Investigator
Steven Roose, MD
Are you between the ages of 21-50? |
Yes |
No |
Have you been diagnosed with Major Depressive Disorder? |
Yes |
No |
Have you tried at least two previous antidepressant treatments that did not work well enough? |
Yes |
No |